Sector: Health Care.Industry: Pharmaceuticals
Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex. It has also completed the development program for DWP-450 for the treatment of moderate to severe glabellar lines.
Earnings
see more| Q1 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2021-05-10 | ||||||
| REV | |||||||
| Q4 2020 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2021-03-09 | ||||||
| REV | |||||||
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| EOLS | Evolus | 0.35% | 388.1M |
Evolus Company Questions & Answers
Q
How do I buy Evolus (EOLS) stock?
A
You can purchase shares of Evolus (NASDAQ: EOLS) through any online brokerage.
Q
Who are Evolus's (EOLS) main competitors?
A
Other companies in Evolus’s space includes: Iterum Therapeutics (NASDAQ:ITRM), Onconova Therapeutics (NASDAQ:ONTX) and WAVE Life Sciences (NASDAQ:WVE).
Q
What is the target price for Evolus?
A
The latest price target for Evolus (NASDAQ: EOLS) was reported by Truist Securities on 2021-02-24. The analyst firm set a price target for 12.00 expecting EOLS to rise to within 12 months (a possible 4.35% upside). 13 analyst firms have reported ratings in the last year.
Q
How much is Evolus (EOLS) stock ?
A
The stock price for Evolus (NASDAQ: EOLS) is $11.5 last updated Thu Feb 25 2021 21:00:02 GMT+0000 (Coordinated Universal Time).
Q
When is the next Evolus (EOLS) dividend?
A
There are no upcoming dividends for Evolus.
Q
When is Evolus (NASDAQ:EOLS) reporting earnings?
A
Evolus’s Q1 earnings are confirmed from now on May 10, 2021.
Q
When is the upcoming split for EOLS?
A
There is no upcoming split for Evolus.